NDC product
Sitagliptin and Metformin Hydrochloride
NDC 70771-1888 · Zydus Lifesciences Limited
Key facts
| Product NDC | 70771-1888 |
|---|---|
| Proprietary name | Sitagliptin and Metformin Hydrochloride |
| Nonproprietary name | sitagliptin and metformin hydrochloride |
| Substances | SITAGLIPTIN, METFORMIN HYDROCHLORIDE |
| Dosage form | TABLET, FILM COATED, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | Zydus Lifesciences Limited |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Application number | NDA216778 |
| Pharmacologic classes | Biguanide [EPC], Biguanides [CS], Dipeptidyl Peptidase 4 Inhibitor [EPC], Dipeptidyl Peptidase 4 Inhibitors [MoA] |
| Marketing start | Oct 31, 2024 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: